Landon Trost, MD, on the significance of the FDA announcement on idiopathic hypogonadism | Urology Times

Trending on Urology Times

Mary Dunn, MSN, NP-C, OCN, RN, on advances reshaping advanced prostate cancer care

Managing Immune-Related Adverse Events With Durvalumab Plus BCG in NMIBC

Precision Medicine and Patient Selection in mHSPC

Inside the POTOMAC Trial: Durvalumab Plus BCG for High-Risk NMIBC

Study shows variability in response to long-term tamsulosin therapy